Nobody asked primary care to become the front door for newer depression treatments. Our data suggests it already is.

In June 2026, 443 adults across a ten-state Midwest footprint told our poll how they would approach ketamine or esketamine care for depression, drawing on the general population rather than a patient list. What emerged is a portrait of what arrives in a primary care exam room before anyone says the word "esketamine," and it has practical consequences for referrers. Every number here is final, post-validation.

Scene one: the patient chooses you

Respondents named their opening move toward this treatment:

  • Their own PCP: 56 percent
  • Psychiatry: 23 percent
  • Independent web research: 12 percent
  • No idea of a starting point: 5 percent
  • A friend: 1 percent

Primary care is chosen more than twice as often as psychiatry and more than four times as often as independent search. This is not a population that shops for mental health treatment online and presents with a request. It is a population that brings the problem to the person who already holds their chart.

Scene two: they are waiting for your opinion

A second item asked which voice would tip them into trying it. Physicians won that question with 74 percent. Friends and relatives drew 18 percent and veterans or first responders with an online following 4 percent, while an ad drew 2 percent and a trusted podcast host 1 percent.

The implication is uncomfortable in a useful way. For most respondents, if their physician says nothing, nothing happens. Direct-to-consumer awareness does not appear to close the decision. Your recommendation does, and so does your silence.

Scene three: they do not know the words

When the question arrives, it will not sound like a treatment request. The name Spravato meant nothing to 73 percent of respondents. A further slice, 21 percent, could place the name but not the drug. Six percent could describe it. Awareness of TMS was only modestly better, at 25 percent.

Asked for the words they would put into a search engine, 319 respondents wrote almost nothing but symptoms and appeals, such as "depressed," "therapist near me," and "ptsd help." Pharmacology was essentially absent.

In practice, the esketamine conversation will usually begin as "the medication is not working" or "is there anything else," often tacked onto a visit booked for something unrelated. The patient is handing you the decision about what to name.

Scene four: the need is already in your panel

Depression, anxiety, or PTSD unresolved by standard medication was part of life for 72 percent of respondents or someone near them: 37 percent personally, 22 percent through a person close to them, 13 percent in both ways.

This is self-report, not diagnosis, and no stand-in for a treatment-resistant depression prevalence figure. It does suggest that inadequate response to standard treatment is a familiar experience in the general population, not a rare specialty presentation.

Scene five: coverage shapes the path

With only two provider priorities allowed, respondents chose coverage at 85 percent and proximity, far behind, at 43 percent. Forced to pick between insurance with extra steps and a simpler cash route, 51 percent picked insurance, 23 percent cash, and 26 percent stayed undecided.

The payer mix matters for referral planning. Commercial coverage led at 39 percent of respondents, Medicaid was a close second at 37 percent, then Medicare 23 percent, no coverage 9 percent, and TRICARE 5 percent, with multiple answers allowed.

Insurers typically want documentation of prior antidepressant trials, adequacy of dose and duration, and symptom scores before approving esketamine. That record usually lives in primary care. You are not only the trusted voice; you are frequently the source of the paperwork.

Scene six: they are open, not eager

Referrers sometimes worry that raising a ketamine-derived treatment will alarm patients. The first-reaction data suggests caution, not hostility. Our first-reaction question found five camps: 34 percent guarded but willing, 21 percent doubtful, 18 percent curious or hopeful, 18 percent who had not heard of ketamine therapy, and only 9 percent against it. Regulatory status is part of what reassures, with 59 percent of respondents rating FDA approval big or deciding. Distinguishing the approved nasal spray from off-label and at-home ketamine is often the most calming thing a physician can say.

What this asks of a referrer

None of this implies that primary care should manage treatment-resistant depression alone, or that esketamine is the right next step for any particular patient. It suggests a few low-cost habits:

  • Translate vague questions. When a patient says "is there anything else," name the options, including psychiatry referral, augmentation, psychotherapy, TMS, and esketamine, and say which you think fit.
  • Document as you go. For every trial, the agent, dose, length, and outcome, alongside a standardized symptom score. It shortens prior authorization later.
  • Know two local destinations. One psychiatry referral point and one certified esketamine site that accepts the plans your panel carries, Medicaid included.
  • Close the loop. A referral that is never scheduled is the most common failure point. A follow-up call or portal message helps.

The one-sentence version

Patients in this sample bring the question to primary care, wait for their doctor's view, and lack the treatment's name. That makes the primary care visit the decisive moment.

Caveats

This is survey research about care-seeking preferences, not clinical evidence. Esketamine (Spravato) carries an adult treatment-resistant depression indication and is dispensed under a REMS, with post-dose observation at certified sites; referrers can point patients to Brain Recovery Centers' overview of what a Spravato course involves. Off-label IV ketamine and home-use ketamine are separate arrangements. Suitability is a clinical judgment.

Any patient in crisis can reach the Suicide and Crisis Lifeline through 988, spoken or texted, day or night. Keeping that number visible in exam rooms and after-visit summaries costs nothing and gives patients a route to help between appointments.

Methodology

Pollfish survey 395586438 ran on the company's consumer panel until June 23, 2026, and yielded 443 completes, respondents 18 through 64, in Iowa, Ohio, Kansas, Wisconsin, Missouri, Oklahoma, Nebraska, Illinois, Minnesota and Indiana. Multi-select items sum above 100. The data are validated and final. The research was ordered and financed by the publisher.